Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are increasingly prescribed in diabetes mellitus (DM) patients, yet their impact on tuberculosis (TB) incidence remains unclear. This evidence concerns the gene SLC5A2 and diabetes mellitus.